2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
- 1 November 2019
- journal article
- research article
- Published by Elsevier BV in Atherosclerosis
- Vol. 290, 140-205
- https://doi.org/10.1016/j.atherosclerosis.2019.08.014
Abstract
No abstract availableKeywords
This publication has 531 references indexed in Scilit:
- Role of Colesevelam in Combination Lipid-Lowering TherapyAmerican Journal of Cardiovascular Drugs, 2013
- Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug TherapyCurrent Cardiology Reports, 2013
- The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stopThe European Journal of Health Economics, 2012
- A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: Results of a meta-analysis of randomized, placebo-controlled trialsProstaglandins, Leukotrienes & Essential Fatty Acids, 2011
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart DiseaseJAMA, 2009
- Contraceptive Hormone Use and Cardiovascular DiseaseJournal of the American College of Cardiology, 2009
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial InfarctionThe American Journal of Cardiology, 2008